Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.92 +2.1%	$4.15	$1.00 ▼ $5.87	$34.09M	0.8	144,307 shs	90,255 shs
IPA ImmunoPrecise Antibodies	$1.11 +19.1%	$0.60	$0.27 ▼ $1.15	$42.67M	0.12	2.49 million shs	1.85 million shs
NKGN NKGen Biotech	$0.22 +2.8%	$0.25	$0.10 ▼ $1.37	$10.07M	1.2	1.57 million shs	83,923 shs
VOR Vor Biopharma	$0.89 +60.5%	$0.35	$0.13 ▼ $1.80	$111.21M	-0.51	3.43 million shs	281.78 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+2.08%	-9.68%	-8.41%	+13.95%	+120.04%
IPA ImmunoPrecise Antibodies	+19.35%	+9.90%	+107.87%	+183.16%	+10.45%
NKGN NKGen Biotech	+2.75%	-10.40%	-21.40%	+37.17%	-82.77%
VOR Vor Biopharma	+60.53%	+315.89%	+412.97%	+18.21%	-22.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.0302 of 5 stars	3.3	3.0	2.2	1.7	0.0
IPA ImmunoPrecise Antibodies	2.2922 of 5 stars	3.5	3.0	2.7	0.0	0.6
NKGN NKGen Biotech	0.8027 of 5 stars	0.0	5.0	0.6	2.5	0.0
VOR Vor Biopharma	3.1768 of 5 stars	4.3	2.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	206.12% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	260.36% Upside
NKGN NKGen Biotech	0.00	N/A	N/A	N/A
VOR Vor Biopharma	2.50	Moderate Buy	$7.06	692.94% Upside

Current Analyst Ratings Breakdown

Latest NKGN, IPA, VOR, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
IPA ImmunoPrecise Antibodies	$18.16M	2.80	N/A	N/A	$0.93 per share	1.19
NKGN NKGen Biotech	$80K	125.85	N/A	N/A	($2.68) per share	-0.08
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-190.76%	-88.87%	-49.26%	7/3/2025 (Estimated)
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest NKGN, IPA, VOR, and ATHE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2025	Q3 2025	IPA ImmunoPrecise Antibodies	-$0.06	-$0.06	N/A	-$0.46	$6.59 million	$4.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
IPA ImmunoPrecise Antibodies	0.45	2.32	2.11
NKGN NKGen Biotech	N/A	0.02	0.02
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
IPA ImmunoPrecise Antibodies	6.70%
NKGN NKGen Biotech	76.17%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
IPA ImmunoPrecise Antibodies	6.83%
NKGN NKGen Biotech	10.36%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
IPA ImmunoPrecise Antibodies	80	45.76 million	42.64 million	Not Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

NKGN, IPA, VOR, and ATHE Headlines

Recent News About These Companies

Vor, with new CEO, changes course to target autoimmune disease

June 26 at 8:41 PM | biopharmadive.comB

After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

June 26 at 8:41 PM | bioworld.comB

Vor Biopharma Insider Trading Activity | NASDAQ:VOR | Benzinga

June 26 at 3:39 PM | benzinga.com

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions

June 26 at 3:39 PM | fiercepharma.comF

Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy

June 26 at 3:39 PM | msn.com

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

June 26 at 11:31 AM | marketbeat.com

Vor Biopharma: Vor Bio Announces $175 Million Private Placement

June 26 at 10:37 AM | finanznachrichten.de

Vor Biopharma: Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 26 at 10:37 AM | finanznachrichten.de

Vor Biopharma stock soars after licensing deal for autoimmune therapy

June 26 at 10:37 AM | investing.com

Wedbush Reaffirms "Neutral" Rating for Vor Biopharma (NYSE:VOR)

June 26 at 10:00 AM | marketbeat.com

Vor Bio Announces $175 Million Private Placement

June 25 at 5:03 PM | globenewswire.com

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset

June 25 at 4:45 PM | globenewswire.com

Estimating The Fair Value Of Vor Biopharma Inc. (NASDAQ:VOR)

June 25 at 1:59 PM | finance.yahoo.com

Vor Biopharma Stock Price History - Investing.com

June 24 at 10:56 PM | investing.com

Vor Biopharma Inc. (VOR) Latest Stock News & Headlines - Yahoo Finance

June 24 at 10:56 PM | finance.yahoo.com

Vor Bio details extent of Cambridge layoffs in state filing

June 2, 2025 | bizjournals.com

Cambridge biotech company researching blood cancers to close, lay off 155

June 2, 2025 | masslive.comM

Vor Biopharma Inc. Advanced Charts - Barron's

May 29, 2025 | barrons.com

RA Capital's biotech incubator lays off staffers: Stat

May 15, 2025 | fiercebiotech.comF

Stifel cuts Vor Biopharma stock rating amid clinical and financial concerns

May 10, 2025 | investing.com

JMP Securities Downgrades Vor Biopharma (VOR)

May 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Which Analyst-Favorite Drone Stock Will Come Out on Top?
By Nathan Reiff | June 25, 2025
View Which Analyst-Favorite Drone Stock Will Come Out on Top?
3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
By Nathan Reiff | June 9, 2025
View 3 Nuclear ETFs to Watch as U.S. Policy Sparks a Surge
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
Broadcom Earnings Preview: AVGO Stock Near Record Highs
By Leo Miller | June 3, 2025
View Broadcom Earnings Preview: AVGO Stock Near Record Highs

NKGN, IPA, VOR, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.92 +0.08 (+2.08%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.10 +0.18 (+4.57%)

As of 06/26/2025 06:05 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ImmunoPrecise Antibodies NASDAQ:IPA

$1.11 +0.18 (+19.06%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.10 -0.01 (-0.45%)

As of 04:29 AM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

NKGen Biotech NYSE:NKGN

$0.22 +0.01 (+2.75%)

As of 06/26/2025 02:50 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Vor Biopharma NYSE:VOR

$0.89 +0.34 (+60.53%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.95 +0.06 (+6.40%)

As of 04:48 AM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time